文献速递胸部头颈技术与安全CTPET

免疫检查点抑制剂治疗患者类结节病反应发生率的回顾性研究

Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy.
PubMed 文献 · Clin Radiol · 2022-11-04

单中心回顾性分析457例接受抗CTLA-4、抗PD-1或联合治疗的转移性黑色素瘤或头颈癌患者,影像学可见的药物性类结节病反应(DISR)发生率为4.1%(19/457)。从免疫治疗开始至DISR出现平均间隔5.5个月,从影像检出至影像学消退平均间隔5.8个月。多数DISR患者无症状且无需全身治疗,多数患者FDG PET/CT未见其他器官SUVmax同步增高。

要点

  • 免疫检查点抑制剂治疗后DISR总体发生率约4.1%,联合治疗组(6.3%)高于单药组(各3.7%)。
  • DISR多出现在免疫治疗后平均5.5个月,影像随访平均5.8个月可消退,多数无症状无需治疗。
  • 阅片时注意FDG PET/CT上DISR多不伴其他器官SUVmax同步增高,有助于与转移/进展鉴别。
英文原文(摘要)· 点击展开

AIM: To assess the frequency of radiographically evident drug-induced sarcoidosis-like reaction (DISR) in patients treated with anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy, anti-programmed cell death protein 1 (PD-1) therapy, or a combination of both in a single centre.

MATERIALS AND METHODS: The images and medical records of 457 patients with metastatic melanoma or head and neck cancer treated with either anti-CTLA-4 therapy, anti-PD-1 therapy, or a combination of both at University of California medical centre were reviewed retrospectively and the incidence of radiological manifestations of DISR was assessed among these treatment groups.

RESULTS: Radiological manifestations of DISR were found in 19/457 patients (4.1%). The mean interval from the initiation of immunotherapy to development of DISR was 5.5 months (range 2.3-13.5 months). Mean interval from radiological detection of DISR to imaging evidence of resolution was 5.8 months (range 1.6-18.3 months). Three patients out of 81 (3.7%), 11/297 (3.7%), and 5/79 (6.3%) developed sarcoidosis-like reaction after treatment with anti-CTLA-4 antibody, anti-PD-1 antibody, and a combination of both, respectively. Most patients with DISR were asymptomatic and did not require systemic therapy. Most patients did not demonstrate concomitant increased maximum standardised uptake value (SUVmax) in other organs on their integrated 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT).

CONCLUSIONS: In the present retrospective study of patients treated with immune checkpoint inhibitors (ICIs), DISR occurred in approximately 3.7% of patients treated with either anti-CTLA-4 or anti-PD-1 antibody and 6.3% of patients treated with a combination of both.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Flavell, Juarez, et al. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol. 2022. PMID: 36344282. doi:10.1016/j.crad.2022.09.127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。